Protagonist raises $18m series B
This article was originally published in Scrip
Menlo Park, California-based Protagonist Therapeutics has raised a total of $18m in a series B financing round, having just received $4m from new investor Pharmastandard International.
You may also be interested in...
J&J's Janssen committed up to $990m plus royalties to collaborate with peptide drug developer Protagonist on an oral IL-23 inhibitor for Crohn's disease, which hits a similar target as two key assets in J&J's immunology portfolio: Stelara and the Phase III biologic guselkumab.
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.
Takeda has managed to persuade NICE, the health technology appraisal institute for England and Wales, to recommend its ulcerative colitis drug Entyvio (vedolizumab) without the restrictions the institute had previously stipulated – as long as the company offers a discount via a patient access scheme.